These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15900794)

  • 21. Alefacept: a novel and selective biologic agent for the treatment of chronic plaque psoriasis.
    Ortonne JP; Prinz JC
    Eur J Dermatol; 2004; 14(1):41-5. PubMed ID: 14965795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alefacept for the treatment of psoriasis and other dermatologic diseases.
    Strober BE; Menon K
    Dermatol Ther; 2007; 20(4):270-6. PubMed ID: 17970892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.
    Krueger GG; Papp KA; Stough DB; Loven KH; Gulliver WP; Ellis CN;
    J Am Acad Dermatol; 2002 Dec; 47(6):821-33. PubMed ID: 12451365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis.
    Perlmutter A; Cather J; Franks B; Jaracz E; Menter A
    J Am Acad Dermatol; 2008 Jan; 58(1):116-24. PubMed ID: 17997502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis.
    Gribetz CH; Blum R; Brady C; Cohen S; Lebwohl M
    J Am Acad Dermatol; 2005 Jul; 53(1):73-5. PubMed ID: 15965424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis.
    Menter A; Cather JC; Baker D; Farber HF; Lebwohl M; Darif M
    J Am Acad Dermatol; 2006 Jan; 54(1):61-3. PubMed ID: 16384756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
    Reich K; Sinclair R; Roberts G; Griffiths CE; Tabberer M; Barker J
    Curr Med Res Opin; 2008 May; 24(5):1237-54. PubMed ID: 18355421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis.
    Ortonne JP
    J Eur Acad Dermatol Venereol; 2003 Jul; 17 Suppl 2():12-6. PubMed ID: 12795770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting T-cell subsets to achieve remission.
    Christophers E
    J Eur Acad Dermatol Venereol; 2003 Jul; 17 Suppl 2():6-11. PubMed ID: 12795769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy.
    Goffe B; Papp K; Gratton D; Krueger GG; Darif M; Lee S; Bozic C; Sweetser MT; Ticho B
    Clin Ther; 2005 Dec; 27(12):1912-21. PubMed ID: 16507377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts.
    Gordon KB; Vaishnaw AK; O'Gorman J; Haney J; Menter A;
    Arch Dermatol; 2003 Dec; 139(12):1563-70. PubMed ID: 14676071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alefacept.
    Frampton J; Wagstaff A
    Am J Clin Dermatol; 2003; 4(4):277-86; discussion 287. PubMed ID: 12680805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alefacept therapy produces remission for patients with chronic plaque psoriasis.
    Krueger GG; Ellis CN
    Br J Dermatol; 2003 Apr; 148(4):784-8. PubMed ID: 12752139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study.
    Koo JY; Bagel J; Sweetser MT; Ticho BS
    J Drugs Dermatol; 2006; 5(7):623-8. PubMed ID: 16865867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of alefacept in elderly patients and other special populations.
    Gottlieb AB; Boehncke WH; Darif M
    J Drugs Dermatol; 2005; 4(6):718-24. PubMed ID: 16302557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Alefacept. Successful long-term therapy of a severe psoriasis].
    Schmitt J; Stoller E; Wozel G
    Hautarzt; 2005 Apr; 56(4):360-2. PubMed ID: 15580452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overview of biologic agents in medicine and dermatology.
    Sobell JM
    Semin Cutan Med Surg; 2005 Mar; 24(1):2-9. PubMed ID: 15900793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of psoriasis on patients' quality of life and improvements associated with alefacept therapy.
    Menter A
    J Cutan Med Surg; 2004 Dec; 8 Suppl 2():20-5. PubMed ID: 15668752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis.
    Legat FJ; Hofer A; Wackernagel A; Salmhofer W; Quehenberger F; Kerl H; Wolf P
    Arch Dermatol; 2007 Aug; 143(8):1016-22. PubMed ID: 17709660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Remittive effects of intramuscular alefacept in psoriasis.
    Gordon KB; Langley RG
    J Drugs Dermatol; 2003 Dec; 2(6):624-8. PubMed ID: 14711140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.